Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies
Open Access
- 9 May 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0320196
Abstract
Objectives: We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries. Methods: Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18–79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated. Results: The proportion of seroreversion was 0% within the four first months, based on Koco19 data (n = 65 participants). In the longer term, 31.3% of participants had seroreverted at 6 months (95%CI: 24.4–39.1) (based on EpiCov data, n = 599), 31.3% (95%CI: 11.0–58.7) at 12 months (based on CON-VINCE data, n = 16). From EpiCov data, both baseline low IgG levels and seroneutralization negativity remained predictive of seroreversion in multivariable analysis. Conclusion: From population-based cohorts, anti-S IgG levels remained stable during the first 4 months following SARS-CoV-2 infection. Most of the decay occurred afterward; nearly one-third of people seroreverted 6 and 12 months later. Low IgG levels and seroneutralization negativity were independent predictors of seroreversion.Keywords
Funding Information
- European Union’s Horizon 2020 (101016167)
- Bavarian State Ministry of Science and the Arts (NA)
- Inserm
- Drees-Direction de la Recherche, des Etudes, de l’Evaluation et des Statistiques (NA)
- Région Ile-de-France
- University of Bielefeld (NA)
- University of Bonn (NA)
- National Research Fund Luxembourg (14716281)
- André Losch Foundation (NA)
- University Hospital (NA)
- LMU Munich (NA)
- German Ministry for Education and Research (01KI20271)
- French Ministry for Research (NA)
- French ministry for health (NA)
- Roche Diagnostics (NA)
- Roche Diagnostics (NA)
- EuroImmun (NA)
- EuroImmun (NA)
- Viramed (NA)
- Viramed
- Mikrogen (NA)
- Mikrogen (NA)
- German Centre for Infection Research DZIF (NA)
- German Centre for Infection Research DZIF (NA)
- Government of Bavaria (NA)
- Government of Bavaria (NA)
- BMW (NA)
- BMW (NA)
- Munich Police (NA)
- Munich Police (NA)
- Accenture (NA)
- Accenture (NA)
- Dr. Box-Betrobox (NA)
- Dr. Box-Betrobox (NA)
- Dr. Becker MVZ (NA)
- Dr. Becker MVZ (NA)
This publication has 42 references indexed in Scilit:
- Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patientsInternal and Emergency Medicine, 2022
- Immunity to SARS-CoV-2 up to 15 months after infectioniScience, 2022
- Anti‐SARS‐CoV‐2 IgG levels in relation to disease severity of COVID‐19Journal of Medical Virology, 2021
- kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care WorkersEuropean Journal of Internal Medicine, 2021
- Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adultsThe Lancet Regional Health - Europe, 2021
- COVID-19 and the Path to ImmunityJAMA, 2020
- Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donorsAntiviral Research, 2020
- Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodiesJournal of Clinical Virology, 2020
- Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgGJournal of Clinical Virology, 2020
- Clinical performance of different SARS‐CoV‐2 IgG antibody testsJournal of Medical Virology, 2020